Login
Aus swaps drug assets with US company
Three firms have advised on a cross-border sale and purchase agreement between Ascent Pharmahealth and Watson Pharmaceuticals.
Digital
Firms: Middletons and Herbert Smith (sellers of Ascent Pharmahealth), Freehills (Watson Pharmaceuticals)
To continue reading the rest of this article, please log in.
Create free account to get unlimited news articles and more!
Deal: Sale of Australian and Southeast Asian generic pharmaceutical business, Ascent Pharmahealth, to US-based Watson Pharmaceuticals
Area: Finance
Value: $375 million
Key players: John Mann (pictured) led the Middletons team while Alan Montgomery led the Herbert Smith team
Deal significance: "This global transaction involving teams in the UK, US, India, Singapore and Australia completed in a little under a month,” said Mann. “The vendor due diligence process was extensive, culminating in a 1,000-page due diligence report being produced in a little over a week."
Ascent’s businesses operate as Ascent Pharmaceuticals in Australia and across Asia under the banners of DHA (Drug Houses of Australia) and Ascent Pharmahealth Asia. The deal includes a network of approximately 300 employees across eight countries in Australia and South East Asia and a manufacturing facility in Singapore.
